1 – 15 of 15
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
- 2023
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
- 2022
-
Mark
New Inhibitors in the Ageing Population : A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
(
- Contribution to journal › Scientific review
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
- 2021
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
(
- Contribution to journal › Article
- 2020
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
- 2015
-
Mark
Strategies for reducing inhibitor formation in severe haemophilia
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
- 2002
-
Mark
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
(
- Contribution to journal › Article
- 2001
-
Mark
Symposium in memory of Professor Inga Marie Nilsson
(
- Contribution to journal › Published meeting abstract
- 1999
-
Mark
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
(
- Contribution to journal › Article
- 1998
-
Mark
The Malmo-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts
(
- Contribution to journal › Scientific review